Could a novel strain of SARS-CoV-2 identified this month be linked to an accelerating spread in the country’s southeast? 

WHO advisors are meeting today to discuss deliberately infecting young, healthy volunteers with SARS-CoV-2 to hasten vaccine development—despite the promising vaccines already on the way.   Pros: Faster results than conventional vaccine field trials…

117 pages of leaked documents reveal that early in the pandemic, China offered the world a partial picture of what they knew and a more optimistic forecast than what was evidenced on the ground.   Despite the virus’s novelty, there was “evidence of clear missteps” and “a…

Less disruptive and costly COVID-19 restrictions can work as well as more intrusive steps like lockdowns to slow the spread of SARS-CoV2, according to a new study ranking the effectiveness of government interventions around the world. The researchers from the Medical…

More good vaccine news broke this morning as biotech company Moderna announced 

A nasal spray designed to block SARS-CoV-2 was completely protective against the virus in a small preprint study of ferrets by Columbia University and other researchers.   Bonus: It’s inexpensive and doesn’t need refrigeration.   If—and it’s still a…

SARS-CoV-2 antibodies wane over time, and more severe cases stir stronger immune responses, a trio of new studies concur. And while they diverge over how long antibodies last, this isn’t necessarily cause for concern.

Some people who have not been exposed to SARS-CoV-2 may still have some immunity to it—and not because they have antibodies.  

Young children infected with SARS-CoV-2 carry high amounts of the viral RNA in their nasal cavities, even if they have only mild symptoms, 

The Moderna candidate vaccine against SARS-CoV-2 generated an immune response and showed no serious adverse effects, the